0001209191-22-030549.txt : 20220519 0001209191-22-030549.hdr.sgml : 20220519 20220519165035 ACCESSION NUMBER: 0001209191-22-030549 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220519 FILED AS OF DATE: 20220519 DATE AS OF CHANGE: 20220519 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Muralidhar Bali CENTRAL INDEX KEY: 0001784138 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39011 FILM NUMBER: 22943809 MAIL ADDRESS: STREET 1: C/O EXICURE, INC. STREET 2: 8045 LAMON AVENUE, SUITE 410 CITY: SKOKIE STATE: IL ZIP: 60077 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EXICURE, INC. CENTRAL INDEX KEY: 0001698530 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 815333008 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2430 N. HALSTED ST. CITY: CHICAGO STATE: IL ZIP: 60614 BUSINESS PHONE: 847-673-1700 MAIL ADDRESS: STREET 1: 2430 N. HALSTED ST. CITY: CHICAGO STATE: IL ZIP: 60614 FORMER COMPANY: FORMER CONFORMED NAME: Max-1 Acquisition Corp DATE OF NAME CHANGE: 20170221 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-05-19 0 0001698530 EXICURE, INC. XCUR 0001784138 Muralidhar Bali C/O EXICURE, INC. 2430 N. HALSTED STREET CHICAGO IL 60614 1 0 0 0 Common Stock 2022-05-19 4 P 0 1472126 0.1937 A 8449126 I See footnotes The shares are held by Abingworth Bioventures VII LP ("Abingworth VII"). Abingworth Bioventures VII GP LP serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP, (together with Abingworth Bioventures VII GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures VII GP LP. Abingworth VII (acting by its general partner Abingworth Bioventures VII GP LP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth VII. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth VII which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth VII. Each of Abingworth VII, Abingworth LLP, the General Partners, the Reporting Person and each member of the investment committee disclaims beneficial ownership of the common stock held by Abingworth VII, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. /s/ John Heard, Attorney-in-Fact 2022-05-19